These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34953734)

  • 1. Treatment of Raynaud phenomenon and ischemic ulcers associated to systemic sclerosis with hyperbaric oxygen.
    Ahijón-Lana M; Baragaño-Ordóñez E; Veiga-Cabello R; de la Cruz-Tapidor C; Carreira PE
    Reumatol Clin (Engl Ed); 2022 Apr; 18(4):246-248. PubMed ID: 34953734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Raynaud Phenomenon and Ischemic Ulcers Associated to Systemic Sclerosis with Hyperbaric Oxygen.
    Ahijón-Lana M; Baragaño-Ordóñez E; Veiga-Cabello R; de la Cruz-Tapidor C; Carreira PE
    Reumatol Clin (Engl Ed); 2021 Jul; ():. PubMed ID: 34229960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raynaud's phenomenon in scleroderma treated with hyperbaric oxygen.
    Dowling GB; Copeman PW; Ashfield R
    Proc R Soc Med; 1967 Dec; 60(12):1268-9. PubMed ID: 6066573
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of hyperbaric oxygen therapy in the treatment of ischemic toe ulcer in a patient presenting systemic sclerosis].
    Poirier E; Wind H; Cordel N
    Ann Dermatol Venereol; 2017 Jan; 144(1):55-59. PubMed ID: 27476378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Raynaud Phenomenon and Digital Ulcers in Scleroderma.
    Cappelli L; Wigley FM
    Rheum Dis Clin North Am; 2015 Aug; 41(3):419-38. PubMed ID: 26210127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raynaud's phenomenon.
    Haque A; Hughes M
    Clin Med (Lond); 2020 Nov; 20(6):580-587. PubMed ID: 33199324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spinal cord stimulation for the treatment of pain and toe ulceration associated with systemic sclerosis: a case report.
    Ito H; Tanei T; Sugawara K; Sando Y; Hori N
    Fukushima J Med Sci; 2022 Apr; 68(1):37-41. PubMed ID: 35228457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Raynaud's phenomenon and sclerodermia].
    Ezquerra Gadea J; López Larrayoz I; García Cores F; García Muñoz M
    Aten Primaria; 2003 Jun; 32(1):60. PubMed ID: 12812693
    [No Abstract]   [Full Text] [Related]  

  • 13. Possible benefit of tadalafil cream for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis.
    Fernández-Codina A; Kazem M; Pope JE
    Clin Rheumatol; 2020 Mar; 39(3):963-965. PubMed ID: 32016657
    [No Abstract]   [Full Text] [Related]  

  • 14. [Potentiating the regional effect of hyperbaric oxygenation in Raynaud's phenomenon].
    Ratner GL; Slutsker GE
    Fiziol Zh (1978); 1991; 37(4):123-7. PubMed ID: 1778248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of biofeedback training in treatment of Raynaud's disease and phenomenon.
    Yocum DE; Hodes R; Sundstrom WR; Cleeland CS
    J Rheumatol; 1985 Feb; 12(1):90-3. PubMed ID: 3981523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma.
    Hummers LK; Wigley FM
    Rheum Dis Clin North Am; 2003 May; 29(2):293-313. PubMed ID: 12841296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight dextran infusions in systemic sclerosis with Raynaud's phenomenon: a report of nine cases.
    Lane P
    Br Med J; 1970 Dec; 4(5736):657-9. PubMed ID: 5488384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic sclerosis - the dermatological perspective.
    Sticherling M
    J Dtsch Dermatol Ges; 2019 Jul; 17(7):716-728. PubMed ID: 31364293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin.
    Garrido-Ríos AA; González-Olivares M; Navarro-Vidal B; Martínez-Morán C; Borbujo J
    Clin Exp Dermatol; 2018 Jun; 43(4):503-505. PubMed ID: 29274125
    [No Abstract]   [Full Text] [Related]  

  • 20. Differences in red cell behaviour between patients with Raynaud's phenomenon and systemic sclerosis and patients with Raynaud's disease.
    Rustin MH; Kovacs IB; Sowemimo-Coker SO; Maddison PJ; Kirby JD
    Br J Dermatol; 1985 Sep; 113(3):265-72. PubMed ID: 3877518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.